FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028

KYNTRA BIO, INC.

Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.
Repaid ~$81M term loan to Morgan Stanley Tactical Value; cash runway now extended into 2028.
Phase 2 monotherapy trial of FG-3246 in mCRPC on track to commence in Q3 2025.
Phase 3 protocol for roxadustat in LR-MDS anemia to be submitted in Q4 2025 after positive FDA meeting.
FibroGen retains roxadustat rights in U.S. and all markets not licensed to Astellas (excl. China/South Korea).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.